Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer
Editorial Group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group
Published Online: 21 OCT 2013
Assessed as up-to-date: 14 AUG 2013
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Lawrie TA, Rabbie R, Thoma C, Morrison J. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010482. DOI: 10.1002/14651858.CD010482.pub2.
- Publication Status: Edited (no change to conclusions)
- Published Online: 21 OCT 2013
This article has been cited by:
- 1Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5), Gynecologic Oncology, 2014, 133, 3, 427, , , , , , , , , ,
- 2MicroRNAs as prognostic markers in ovarian cancer, Molecular and Cellular Endocrinology, 2014, 390, 1-2, 73, , , , , , , , , , , , , , , , , , , , ,